IL-10 contributes to the formation of an immunosuppressive tumor microenvironment (TME) in cancers such as gastric, ovarian, bladder, and pancreatic cancers and is correlated with poor patient outcomes [30–32]. This evidence concerns the gene IL10 and pancreatic neoplasm.